Navigation Links
Bionovo Announces Closing of Follow-on Offering of Common Stock and Warrants
Date:2/2/2011

the transaction. Lifetech Capital (a division of Aurora Capital) acted as an advisor on the transaction.

These securities were offered and sold pursuant to a registration statement (File No. 333-171208) that was declared effective by the Securities and Exchange Commission on January 28, 2011. This news release does not constitute an offer to sell or a solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offer of these securities will be solely by means of a prospectus included in the registration and any prospectus supplement that may be issued with respect to such offering. You may obtain copies of the final prospectus relating to the offering for free by visiting EDGAR on the SEC's website, at www.sec.gov.  Alternatively, copies of the prospectus may be obtained from the offices of Cowen and Company, LLC (c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attn: Prospectus Department (631) 254-7106).

About Menerba

Menerba is an oral botanical drug candidate designed for the safe, effective treatment of vasomotor symptoms (hot flashes) associated with menopause. Menerba is an estrogen receptor beta (ER-b) selective drug, developed as an alternative to the products currently on the market which have been shown to increase the risk for breast and uterine cancers. It has been shown that the increased risk of breast and uterine cancers is associated with activation of estrogen receptor alpha (ER-a) and that activation of estrogen receptor beta (ER-b) blocks the growth promoting effects on breast cancer cells. The active ingredients in Menerba are derived from botanicals with centuries of recorded safe, effective use in traditional
'/>"/>

SOURCE Bionovo, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Bionovo, Inc. to Announce First Quarter Fiscal Year 2010 Financial Results on Tuesday, May 11, 2010
2. Bionovo Announces Publication Describing First Novel Dual mTOR Inhibitor, BN107, for the Treatment of Breast Cancer
3. Bionovo to Present on Novel Female-Specific Drugs for Obesity at the 20th Annual Meeting of the North American Menopause Society
4. Bionovo, Inc. to Announce Second Quarter Fiscal Year 2009 Financial Results on Monday, August 10, 2009
5. Bionovo Appoints Dr. Klaus Kohl as Chief Technical Officer
6. Bionovo Announces Publication of Data on Active Compound and Mechanism of Action for Its Preclinical Cancer Treatment, BN108
7. Bionovo Announces 2008 Highlights and Year-End Financial Results
8. Bionovo Announces Publication of Positive Phase 2 Trial Results for Menerba(TM)
9. Bert W. OMalley, M.D., Recipient of the 2008 National Medal for Science, Joins Bionovos Scientific Advisory Board
10. Bionovo Publishes Discoveries in Predictable Tissue Selectivity for Selective Estrogen Receptor Modulators Platform
11. Bionovo to Present Recent Findings of BN107, its Anticancer Agent, at the 31st Annual San Antonio Breast Cancer Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... Research and Markets  has announced the ... Global Industry Analysis, Size, Share, Growth, Trends and Forecast ... http://photos.prnewswire.com/prnh/20130307/600769 Transfection is ... or RNA) into cells. This technology helps the cells ... protein metabolism by affecting the nuclear genes. The transfection ...
(Date:7/11/2014)... BCC Research ( http://www.bccresearch.com ) reveals in ... (PCR) TECHNOLOGY: GLOBAL MARKETS , the global market for ... billion in 2013. This is estimated to grow to ... growth rate (CAGR) of 28.6%. , New digital PCR ... possibilities within the broader PCR field. The opportunities presented ...
(Date:7/11/2014)... EPFL and the University of  Geneva  (UNIGE) ... P. Donoghue . The American neuroscientist is to head ... The new Wyss Center for Bio- and Neuro-Engineering, ... , has named as its director one of the ... founder of Brown University,s Institute for Brain Science, has ...
(Date:7/11/2014)... ON , July 11, 2014 /CNW/ - Sunovion ... approved APTIOM TM (eslicarbazepine acetate) for use as ... seizures in patients with epilepsy who are not satisfactorily ... indicated for use in patients under 18 years of ... most common neurological disorders and according to Epilepsy Canada, ...
Breaking Biology Technology:International Transfection Technology Market - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2019 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 3John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 2John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4
... Cell Therapeutics (CTI),(Nasdaq and MTA: CTIC) announced today that ... on February 27, 2009 in lieu of the Special,Meeting ... February 6, 2009.,Shareholders of record at the close of ... the Board of Directors, will be entitled to vote ...
... NVAX ) a clinical-stage vaccine company, announced ... Officer, will be presenting at the Phacilitate Vaccine Forum ... Grand Hyatt in Washington D.C. Dr. Heaton is ... technologies and other novel vaccine manufacturing solutions providing in ...
... Geron to Study GRNOPC1 in Patients with Acute Spinal Cord ... GERN ) announced that the U.S. Food and Drug,Administration ... application for the clinical trial of GRNOPC1 in patients with,acute ... with,the world,s first study of a human embryonic stem (hESC) ...
Cached Biology Technology:Novavax CMO to Present at Phacilitate Vaccine Forum Washington 2009 2Novavax CMO to Present at Phacilitate Vaccine Forum Washington 2009 3MultiVu Video Feed: Geron Receives FDA Clearance to Begin World's First Human Clinical Trial of Embryonic Stem Cell-Based Therapy 2
(Date:7/11/2014)... July 10, 2014---A team of researchers from The Chinese ... identified a gene of wild soybean linked to salt ... grow in saline soil. This study published online in ... unveil novel genomic information for crop improvement. , Soybean ... domestication and human selection, cultivated soybeans have less genetic ...
(Date:7/11/2014)... Salk Institute for Biological Studies, BGI, and other ... and reliability of the existing targeted gene correction ... which could significantly increased gene-correction efficiency in human ... online in Cell Stell Cell provides ... therapy. , The combination of stem cells and ...
(Date:7/11/2014)... often develop relationships with other group members to reduce ... chacma baboons the strategy for grooming activities shows a ... published in the scientific journal Biology Letters . ... is not practiced without ulterior motives. To be groomed ... individual, while grooming another individual can provide access to ...
Breaking Biology News(10 mins):BGI reports a novel gene for salt tolerance found in wild soybean 2A new genome editing method brings the possibility of gene therapies closer to reality 2Baboons groom early in the day to get benefits later 2
... is a professional, scientific society of approximately 11,000 ... research institutes worldwide. Founded in 1986, AAPS provides ... knowledge among scientists to serve the public and ... scientific programs, on-going education, information resources, opportunities for ...
... Following the drought of 2012, the prices of ... significantly. In an effort to reduce their costs, pork ... and phosphorus (P). Researchers at the University of Illinois ... minerals in byproducts from the rendering industry. Professor ...
... Park Ridge, Ill. (April 23, 2013) This ... the world are gathering to share research on a ... growing global burden of chronic disease, there is particular ... in overall health. Several studies presented at the conference ...
Cached Biology News:2013 AAPS National Biotechnology Conference returns to San Diego 2Calculating phosphorus and calcium concentrations in meat and bone meal for pig diets 2New research points to benefits of eggs, even for those at cardiovascular risk 2
Hybridization Buffer 3.6 ml...
Olig2 Immunogen: Synthetic peptide from rat. Available Date: 9-19-2006...
Mouse monoclonal [0.N.305] to G protein alpha - BSA and Azide free ( Abpromise for all tested applications). Antigen: Partially purified G protein alpha from rat brain. Entrez GeneID: 2778 ...
Proteinase K Buffer 3.9 ml...
Biology Products: